Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totaling 25,074 shares, a decrease of 64.5% from the August 31st total of 70,645 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 214,273 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Astellas Pharma Trading Down 1.8%

Shares of Astellas Pharma stock opened at $14.95 on Tuesday. The firm has a market capitalization of $27.05 billion, a PE ratio of 11.38 and a beta of 0.08. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.20 and a quick ratio of 0.93. The company’s fifty day moving average price is $14.59 and its two-hundred day moving average price is $14.53. Astellas Pharma has a 52-week low of $10.03 and a 52-week high of $17.35.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.